Chugai Pharmaceutical Co ((CHGCF)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Chugai Pharmaceutical Co, in collaboration with Hoffmann-La Roche, is conducting a Phase III clinical study titled ‘A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.’ The study aims to assess the effectiveness and safety of the drug combination of divarasib and pembrolizumab compared to the standard treatment of pembrolizumab with pemetrexed and carboplatin or cisplatin in treating advanced lung cancer.
Intervention/Treatment: The study is testing two treatment regimens. The experimental group receives divarasib, an oral medication taken daily, and pembrolizumab, administered via intravenous infusion every three weeks. The comparator group receives pembrolizumab, pemetrexed, and either carboplatin or cisplatin, all given intravenously every three weeks.
Study Design: This interventional study is randomized with a parallel assignment model, meaning participants are randomly assigned to one of the two treatment groups. There is no masking, and the primary purpose is treatment, focusing on evaluating the efficacy and safety of the drug combinations.
Study Timeline: The study began on January 20, 2025, with the latest update submitted on October 3, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
Market Implications: The outcome of this study could significantly impact Chugai Pharmaceutical’s stock performance and investor sentiment. A successful trial may enhance Chugai’s competitive position in the oncology market, particularly in treating KRAS G12C-mutated lung cancer, a segment with growing interest and competition.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.